{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T09:17:43Z","timestamp":1695633463697},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Early-stage classic Hodgkin lymphoma has been highly curable using extended-field radiation therapy (RT) alone, combined-modality therapy consisting of chemotherapy and RT, and more recently chemotherapy alone. Radiation therapy either to an extended field (extended-field RT) or to various iterations of an involved field (involved-field RT) is potentially associated with late morbidity and mortality, particularly second primary cancers and cardiovascular complications. Treatment with chemotherapy alone, when possible, can achieve a high cure rate while avoiding these risks. This review describes the evolution of treatment for early-stage classic Hodgkin lymphoma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000329","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T09:55:42Z","timestamp":1538646942000},"page":"223-229","source":"Crossref","is-referenced-by-count":1,"title":["Limited-Stage Hodgkin Lymphoma"],"prefix":"10.1097","volume":"24","author":[{"given":"David J.","family":"Straus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"djv018","DOI":"10.1093\/jnci\/djv018","article-title":"Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood","volume":"107","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R","article-title":"The significance of mediastinal involvement in early stage Hodgkin's disease","volume":"42","year":"1978","journal-title":"Cancer"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","year":"1989","journal-title":"J Clin Oncol"},{"key":"bib4-20230924","first-page":"1232","article-title":"Prophylactic treatment of adjacent areas in Hodgkin's disease","volume":"26","year":"1966","journal-title":"Cancer Res"},{"key":"bib5-20230924","first-page":"139","article-title":"Hodgkin's disease. Modern radiotherapy techniques and their results","volume":"6","year":"1973","journal-title":"Ser Haematol"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","year":"2006","journal-title":"J Clin Oncol"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial","volume":"25","year":"2007","journal-title":"J Clin Oncol"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1200\/JCO.2003.12.086","article-title":"Randomized comparison of ABVD and MOPP\/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial","volume":"21","year":"2003","journal-title":"J Clin Oncol"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijrobp.2017.10.015","article-title":"Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORT-GELA H9-F Intergroup Randomized Trial","volume":"100","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy","volume":"28","year":"2010","journal-title":"J Clin Oncol"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","year":"2006","journal-title":"Radiother Oncol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ijrobp.2014.04.026","article-title":"Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients","volume":"89","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2004-04-1311","article-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","volume":"104","year":"2004","journal-title":"Blood"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2010-10-314260","article-title":"Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I\/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET","volume":"117","year":"2011","journal-title":"Blood"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2013.53.2838","article-title":"In vivo treatment sensitivity testing with positron emission tomography\/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography\u2013negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaoncol.2015.4794","article-title":"Radiation therapy for Hodgkin lymphoma\u2014can it be administered more safely if necessary?","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.1991.9.2.227","article-title":"Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment","volume":"9","year":"1991","journal-title":"J Clin Oncol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2015.01.048","article-title":"Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group","volume":"92","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.V126.23.579.579","article-title":"Advanced stage classical hodgkin lymphoma patients with a negative PET-scan following treatment with ABVD have excellent outcomes without the need for consolidative radiotherapy regardless of disease bulk at presentation","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.V130.Suppl_1.734.734","article-title":"A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","volume":"130","year":"2017","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:11:52Z","timestamp":1695532312000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00130404-201809000-00004"}},"subtitle":["Minimizing Toxicity"],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000329","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}